82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies

A.G. Gianoukakis, S.M. Arnold, S.A. Kahn, M. Taylor, E. Garralda, M.G. Krebs, H-T. Arkenau, L. Clark, G. Fisher, V. Subbiah

Research output: Contribution to conferenceAbstractpeer-review

Original languageEnglish
PagesS87-S88
DOIs
Publication statusPublished - 1 Apr 2023
EventEuropean Lung Cancer Congress 2023 - Copenhagen, Denmark
Duration: 29 Mar 20231 Apr 2023

Conference

ConferenceEuropean Lung Cancer Congress 2023
Abbreviated titleELCC 2023
Country/TerritoryDenmark
CityCopenhagen
Period29/03/231/04/23

Cite this